Test-tube baby-making market is ready to pop

Jinxin Fertility

03/06/2021 20:28

(The author is a Reuters Breakingviews columnist.  The opinions
expressed are her own.)
    By Lauren Silva Laughlin
    NEW YORK, June 3 (Reuters Breakingviews) - Declining sperm
counts, delayed fertility decisions and lower birth rates are
trends fueling an investment segment casually known as
“femtech.” Societal and governmental reluctance can get in the
way of financial returns. But for investors, where there's a
will, there’s a way. 
    Full view will be published shortly.
    Follow @thereallsl https://twitter.com/thereallsl on Twitter

    CONTEXT NEWS
    - In December 2019, Santa Monica Fertility said that it
would be bought by Webster Equity Partners, a private equity
firm, for an undisclosed price. Dresner Partners advised Santa
Monica Fertility on the deal. 
    - Private equity firm TPG invested in Progyny, a fertility
benefits management company, in 2016. The company went public in
2019. In 2018, Warburg Pincus invested in China-based Jinxin
Fertility. The company listed shares in 2019.  
    - For previous columns by the author, Reuters customers can
click on  SILVA/ 


    <^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
BREAKINGVIEWS-Will casual sex get shafted by the pandemic?   
 urn:newsml:reuters.com:*:nL1N2CO0UZ
    ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>
 (SIGN UP FOR BREAKINGVIEWS EMAIL ALERTS http://bit.ly/BVsubscribe
 | Editing by Richard Beales and Amanda Gomez)
 ((Lauren.SilvaLaughlin@thomsonreuters.com))